NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in clinical trials for the treatment of glioblastoma; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration to patients with primary and secondary brain tumors. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. NeOnc Technologies Holdings, Inc. was incorporated in 2005 and is based in Calabasas, California.
Metrics to compare | NTHI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNTHIPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.9x | −0.3x | −0.5x | |
PEG Ratio | 0.01 | 0.00 | 0.00 | |
Price/Book | −9.2x | 0.9x | 2.6x | |
Price / LTM Sales | 1,106.1x | 1.6x | 3.3x | |
Upside (Analyst Target) | - | 107.1% | 42.8% | |
Fair Value Upside | Unlock | 7.7% | 6.5% | Unlock |